← All trials
NCT00560053
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2000
- Primary completion
- —
- Completion date
- Feb 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PETHEMA FoundationLead sponsor
- Hospital Universitari Son DuretaStudy chair
- University of BarcelonaStudy chair
- Hospital Doce de Octubre MadridStudy chair
- Hospital Clinico MadridStudy chair
- University of ValenciaStudy chair
- University of CantabriaStudy chair
- Universidad Autonoma de MadridStudy chair
- Universidad Complutense de MadridStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.